<DOC>
	<DOCNO>NCT00004204</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient recurrent progressive malignant glioma .</brief_summary>
	<brief_title>Temozolomide Treating Patients With Recurrent Progressive Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival response rate patient recurrent progressive malignant glioma treat temozolomide . - Determine whether certain category malignant glioma , oligodendroglioma , sensitive temozolomide . - Determine toxicity regimen patient . OUTLINE : Patients stratify accord histologic category ( recurrent glioblastoma multiforme [ close accrual 11/30/01 ] v recurrent anaplastic astrocytoma v recurrent anaplastic oligodendroglioma ) . Patients receive oral temozolomide twice daily 5 consecutive day . Courses repeat every 28 day 1 year absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 100 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent progressive malignant glioma one follow type : Anaplastic oligodendroglioma oligoastrocytoma Anaplastic astrocytoma Glioblastoma multiforme ( stratum close accrual 11/30/01 ) Patients fail radiotherapy eligible Measurable disease CT scan MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Hepatic : SGOT SGPT less 3 time upper limit normal ( ULN ) Alkaline phosphatase less 2 time ULN ( great 2 time ULN gamma glutamyl transferase test must perform ) Renal : BUN le 1.5 time ULN Creatinine less 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No serious concurrent infection medical illness would preclude study entry No frequent vomit partial bowel obstruction HIV negative No AIDSrelated illness No concurrent malignancy except carcinoma situ cervix basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent epoetin alfa Chemotherapy : At least 6 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy ( exception allow recurrent/progressive disease discretion primary investigator ) Surgery : Recovered prior surgery Other : No concurrent investigational agent Concurrent anticonvulsant therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
</DOC>